Boehringer and Lupin Settle Patent Suit on Spiriva HandiHaler

Boehringer had claimed that Lupin’s proposed generic version of its Spiriva HandiHaler would infringe a patent for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, or COPD.

• Lupin is blocked from making copies until patent has expired “unless otherwise specifically authorized,” according to consent judgment and order of permanent injunction, approved Thursday in federal court in Newark, New Jersey
• Boehringer filed suit in August 2018
• Bench trial had been set for January 2022
• Patent expires in September 2027: FDA Orange Book
• Spiriva had sales of 1.79 million euros ($2.1 million) in 2020, down 13% from 2019, ...